Prana Biotechnology Limited (ADR) (Public, NASDAQ:PRAN) part of our HIDDEN GEM portfolio has reached the point for a potential pop up. Besides use against Alzhiemers its new business strategy include Huntington's Disease which would help it to target market approval for PBT2 at less time and cost.